论文部分内容阅读
目的:探讨国内弥漫性大B细胞淋巴瘤(DLBCL)免疫表型分型及BCL-2和BCL-6基因异常的分布情况。方法:应用组织芯片和免疫组织化学法及FISH技术对219例DLBCL的免疫表型及BCL-2和BCL-6基因异常进行检测,根据Hans法进行分型;并收集国内7家相关研究报道,进行综合分析。结果:本组研究结果:219例DLBCL中,非GCB型(165例,75.3%)显著高于GCB型(54例,24.7%)(P<0.001)。BCL-2基因异常共49例(25.8%),其中t(14;18)5例(2.6%)均为GCB型;BCL-2基因扩增44例(23.2%),GCB型4例(8.5%),非GCB型40例(28.0%),有显著性差异(P=0.013)。BCL-6基因重排共42例(22.1%),GCB型7例(14.9%),非GCB型35例(24.5%),差异无统计学意义(P=0.189)。BCL-2基因扩增和BCL-6基因重排呈显著负相关(r=-0.180,P=0.013) 8组综合分析:1 259例中非GCB型(879例,69.8%)明显高于GCB型(380例,30.2%)(P<0.001);免疫表型中CD10和MUMl阳性率组间差异较小(P=0.047和P=0.048),而BCL-6及BCL-2阳性率组间存在明显差异(P<0.001)。结论:我国DLBCL患者在主要免疫表型和遗传学特征方面具有独特性,对此值得进行深入研究。
Objective: To investigate the immunophenotype and the distribution of BCL-2 and BCL-6 gene in diffuse large B-cell lymphoma (DLBCL) in China. Methods: The immunophenotypes of 219 cases of DLBCL and the abnormalities of BCL-2 and BCL-6 genes were detected by tissue microarray, immunohistochemistry and FISH and classified according to the Hans method. Seven domestic research reports were collected, For a comprehensive analysis. Results: The results of this study showed that in 219 cases of DLBCL, non-GCB type (165 cases, 75.3%) was significantly higher than GCB type (54 cases, 24.7%) (P <0.001). There were 49 cases (25.8%) with BCL-2 gene abnormalities, of which 5 cases (2.6%) were genotype GCB with t (14; 18) %), Non-GCB 40 cases (28.0%), there was a significant difference (P = 0.013). There were 42 cases (22.1%) with BCL-6 gene rearrangement, 7 cases (14.9%) with GCB type and 35 cases (24.5%) with non-GCB type. The difference was not statistically significant (P = 0.189). There was a significant negative correlation between BCL-2 gene amplification and BCL-6 gene rearrangement (r = -0.180, P = 0.013). 8 Comprehensive analysis: 1 259 GCB cases (879 cases, 69.8% (P <0.001). There was no significant difference in the immunophenotype among the positive rates of CD10 and MUM1 (P = 0.047 and P = 0.048), but between BCL-6 and BCL-2 positive rates There was a significant difference (P <0.001). Conclusion: DLBCL patients in our country are unique in their major immunophenotypic and genetic characteristics, which deserves further study.